<DOC>
	<DOCNO>NCT01752335</DOCNO>
	<brief_summary>The purpose study determine whether tocilizumab change cardiovascular risk factor patient arthritis rheumatoid . Study hypothesis : IL-6 contributes increase cardiovascular risk factor patient rheumatoid arthritis produce systemic effect increase weight atherogenic body fat , change energy homeostasis induce adipokines production insulin resistence .</brief_summary>
	<brief_title>Effect Monoclonal Anti-IL6 Antibody ( Tocilizumab ) Cardiovascular Risk Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Age ≥ 18 &lt; 70 year . 2 . Diagnosis active Rheumatoid Arthritis , moderate severe ( ≥ 3.2 DAS28 ) ≥ 6 month duration . 3 . Patients inadequate clinical response stable dose nonbiological DMARDs antiTNF treatment period ≥ 8 week treatment . 4 . If patient receive oral corticosteroid , dose ≤ 10 mg predinosona stable least one month start treatment ( day 1 ) . 5 . Patients able wish sign inform consent comply requirement study protocol . 1 . Major surgery ( include joint surgery ) within eight week prior screen visit major surgery schedule six month first infusion . 2 . Other Rheumatic autoimmune disease , include systemic lupus erythematosus ( SLE ) , mixed connective tissue disease ( MCTD ) , scleroderma , polymyositis systemic involvement secondary AR ( vasculitis , pulmonary fibrosis Felty 's syndrome ) . It 's allow inclusion patient interstitial pulmonary fibrosis still able tolerate treatment MTX . Sjögren 's syndrome RA consider exclusion criterion . 3 . Rheumatoid arthritis Functional Class IV define RA Classification ACR ( complete significant disability patient , confine bed wheelchair without possibility take care ) . 4 . Prior actual inflammatory joint disease different RA ( eg , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ) . Specific drug criterion 5 . Treatment investigational agent four week screen visit ( time equivalent five halflives investigational drug , whichever long ) . 6 . Immunization live vaccine / attenuate four week prior baseline visit . 7 . Pretreatment TCZ Laboratory Tests ( screen visit ) 8 . Serum creatinine &gt; 142 mmol / l ( 1.6 mg / dL ) woman &gt; 168 mmol / l ( 1.9 mg / dl ) men absence active renal disease . 9 . ALT ( SGPT ) AST ( SGOT ) &gt; 1.5 ULN ( initial sample ALT [ SGPT ] AST [ SGOT ] give value &gt; 1.5 time ULN , take analyze second sample selection period ) . 10 . Platelet count &lt; 100 x 109 / l ( 100.000/mm3 ) . 11 . Hemoglobin &lt; 85 g / dl ( &lt; 8.5 g / l , 5.3 mmol / l ) . 12 . Leukocytes &lt; 1.0 x 109 / l ( 1000/mm3 ) , ANC &lt; 0.5 x 109 / L ( 500/mm3 ) . 13 . RAL &lt; 0.5 x 109 / L ( 500/mm3 ) . 14 . Positivity surface antigen hepatitis B ( HBsAg ) antibodies hepatitis C. 15 . Total bilirubin &gt; ULN ( initial sample bilirubin &gt; ULN , take analyze second sample selection period ) . 16 . Triglycerides &gt; 10 mmol / l ( &gt; 900 mg / dl ) screen visit ( non fasting ) . 17 . Pregnant lactating woman . 18. use reliable mean contraception , physical barrier ( patient partner ) , pill contraceptive patch , spermicide barrier IUD . 19 . Background serious allergic anaphylactic reaction human monoclonal antibody , humanize murine . 20 . RXT evidence clinically significant abnormality . 21 . Evidence uncontrolled concomitant serious illness , cardiovascular , nervous system , lung ( include obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) , gastrointestinal . 22. history diverticulitis , diverticulosis antibiotic treatment , physician consider benefitrisk ratio . 23 . Background low GI ulcer disease Crohn 's disease , ulcerative colitis symptomatic condition predispose perforation low GI 24 . Uncontrolled disease asthma , psoriasis inflammatory bowel disease , ... treat normally corticosteroid orally parenterally . 25 . Ongoing liver disease determine principal investigator . ( Patients history elevate ALT ( SGPT ) exclude ) 26 . Active infection recurrent infection past mycobacteria , fungus , virus bacteria ( example : tuberculosis , atypical mycobacterial disease , clinically significant abnormality RXT , hepatitis B C , herpes zoster ) , major episode infection require hospitalization IV antibiotic treatment 4 week precede screen visit oral antibiotic 2 week prior screen visit . 27 . Primary secondary immunodeficiency . 28 . Evidence active malignancy diagnose within 5 year inclusion ( include solid tumor hematological ) , breast cancer diagnose previous 5 year . 29 . Active tuberculosis ( TB ) require treatment within 3 year . Patients positive skin test tuberculin purify protein derivative ( PPD ) screen visit . Patients treat tuberculosis recurrence last three year exclude . 30 . HIV positive patient . 31 . History alcoholism , drug addiction drug abuse six month screen visit . 32 . Painful neuropathy condition may interfere pain assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid Arthritis , tocilizumab , cardiovascular risk factor</keyword>
</DOC>